United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by Cerity Partners LLC

Cerity Partners LLC lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 37.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,243 shares of the biotechnology company's stock after selling 4,345 shares during the quarter. Cerity Partners LLC's holdings in United Therapeutics were worth $2,233,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of UTHR. Dunhill Financial LLC lifted its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics during the 1st quarter valued at $49,000. State of Wyoming acquired a new position in shares of United Therapeutics during the 4th quarter valued at $62,000. Curat Global LLC acquired a new position in shares of United Therapeutics during the 1st quarter valued at $63,000. Finally, Millstone Evans Group LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $67,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $285.57, for a total value of $856,710.00. Following the completion of the sale, the director owned 1,750 shares of the company's stock, valued at $499,747.50. This trade represents a 63.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,681 shares of company stock valued at $22,140,089 over the last three months. Company insiders own 10.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on UTHR. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley lowered their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Bank of America reduced their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Cantor Fitzgerald began coverage on United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $383.08.

United Therapeutics Trading Down 1.8%

United Therapeutics stock opened at $292.01 on Friday. The firm has a 50-day moving average price of $300.42 and a 200-day moving average price of $317.89. The firm has a market capitalization of $13.17 billion, a PE ratio of 11.65, a price-to-earnings-growth ratio of 6.31 and a beta of 0.53. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business's revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business posted $6.17 EPS. As a group, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.